Myofibroblast-Derived SFRP1 as Potential Inhibitor of Colorectal Carcinoma Field Effect

• Gábor Valcz ,

  Contributed equally to this work with: Gábor Valcz, Árpád V. Patai

  Affiliation Molecular Medicine Research Unit, Hungarian Academy of Sciences, Budapest, Hungary

  ⨯
• Árpád V. Patai ,

  Contributed equally to this work with: Gábor Valcz, Árpád V. Patai

  * E-mail: arpad.patai@gmail.com

  Affiliation 2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary

  ⨯
• Alexandra Kalmár,

  Affiliation 2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary

  ⨯
• Bálint Péterfia,

  Affiliation 2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary

  ⨯
• István Fűri,

  Affiliation 2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary

  ⨯
• Barnabás Wichmann,

  Affiliation Molecular Medicine Research Unit, Hungarian Academy of Sciences, Budapest, Hungary

  ⨯
• Györgyi Műzes,

  Affiliation 2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary

  ⨯
• Ferenc Sipos,

  Affiliation 2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary

  ⨯
• Tibor Krenács,

  Affiliation 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary

  ⨯
• Emese Mihály,

  Affiliation 2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary

  ⨯
• Sándor Spisák,

  Affiliation Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Béla Molnár,

  Affiliations Molecular Medicine Research Unit, Hungarian Academy of Sciences, Budapest, Hungary, 2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary

  ⨯
• Zsolt Tulassay

  Affiliations Molecular Medicine Research Unit, Hungarian Academy of Sciences, Budapest, Hungary, 2nd Department of Internal Medicine, Semmelweis University, Budapest, Hungary

  ⨯